NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones

Biochemical Pharmacology

Volumn 83, Issue 8, 2012, Pages 1033-1040

  Siegel, David ^a   Yan, Chao ^a   Ross, David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

NQO1; Polymorphism; Quinone

Indexed keywords

ALVESPIMYCIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BENZOQUINONE; BETA LAPACHONE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HYDROQUINONE; LEUCOMITOMYCIN C; MITOMYCIN C; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RETASPIMYCIN; TANESPIMYCIN; UNCLASSIFIED DRUG;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; BIOCHEMISTRY; BIOREDUCTIVE ACTIVATION; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CHEMOSENSITIVITY; CYTOTOXICITY; DETOXIFICATION; DNA CROSS LINKING; DNA POLYMORPHISM; DRUG ACTIVATION; DRUG STRUCTURE; GENE OVEREXPRESSION; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; DRUG RESISTANCE, NEOPLASM; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; NEOPLASMS; POLYMORPHISM, GENETIC; QUINONES; RIFABUTIN;

EID: 84858005998     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.12.017     Document Type: Review

References (117)

1. Vasiliou V, Ross D, Nebert DW. Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family. Hum Genomics 2006;2:329-35.
2. Lind C, Cadenas E, Hochstein P, Ernster L. DT-diaphorase: purification, properties, and function. Methods Enzymol 1990;186:287-301. (Pubitemid 20279970)
3. Faig M, Bianchet MA, Talalay P, Chen S, Winski S, Ross D, et al. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc Natl Acad Sci USA 2000;97:3177-82. (Pubitemid 30183275)
4. Bianchet MA, Faig M, Amzel LM. Structure and mechanism of NAD[P]H:quinone acceptor oxidoreductases (NQO). Methods Enzymol 2004;382:144-74. (Pubitemid 38240789)
5. Winski SL, Koutalos Y, Bentley DL, Ross D. Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. Cancer Res 2002;62:1420-4. (Pubitemid 34407801)
6. Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 2000;29:246-53.
7. Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H:-quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 1998;4:2065-70. (Pubitemid 28415648)
8. Strassburg A, Strassburg CP, Manns MP, Tukey RH. Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue. Mol Pharmacol 2002;61:320-5. (Pubitemid 34112806)
9. Schor NA, Morris HP. The activity of the D-T diaphorase in experimental hepatomas. Cancer Biochem Biophys 1977;2:5-9. (Pubitemid 8165457)
10. Cresteil T, Jaiswal AK. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 1991;42:1021-7.
11. Schlager JJ, Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 1990;45:403-9. (Pubitemid 20087182)
12. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992;52:797-802.
13. Chen S, Wu K, Zhang D, Sherman M, Knox R, Yang CS. Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling. Mol Pharmacol 1999;56:272-8. (Pubitemid 29347602)
14. Tsvetkov P, Adamovich Y, Elliott E, Shaul Y. E3 ligase STUB1/CHIP regulates NAD(P)H:quinone oxidoreductase 1 (NQO1) accumulation in aged brain, a process impaired in certain Alzheimer disease patients. J Biol Chem 2011;286:8839-45.
15. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 2001;59:263-8. (Pubitemid 32108559)
16. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 1999;9:113-21. (Pubitemid 29176730)
17. Gaedigk A, Tyndale RF, Jurima-Romet M, Sellers EM, Grant DM, Leeder JS. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics 1998;8:305-13. (Pubitemid 28372324)
18. Kelsey KT, Ross D, Traver RD, Christiani DC, Zuo ZF, Spitz MR, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 1997;76:852-4. (Pubitemid 27401934)
19. Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 2004;382:115-44. (Pubitemid 38240788)
20. Pan SS, Forrest GL, Akman SA, Hu LT. NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells. Cancer Res 1995;55:330-5.
21. Hu LT, Stamberg J, Pan S. The NAD(P)H:quinone oxidoreductase locus in human colon carcinoma HCT 116 cells resistant to mitomycin C. Cancer Res 1996;56:5253-9. (Pubitemid 26383044)
22. Begleiter A, Robotham E, Leith MK. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia. Mol Pharmacol 1992;41:677-82. (Pubitemid 23021455)
23. Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar SG, Sartorelli AC. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1. Cancer Res 1984;44:5638-43. (Pubitemid 15183570)
24. Siegel D, Gibson NW, Preusch PC, Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990;50:7483-9.
25. Marshall RS, Paterson MC, Rauth AM. Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual. Biochem Pharmacol 1991;41:1351-60.
26. Marshall RS, Paterson MC, Rauth AM. DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family. Carcinogenesis 1991;12:1175-80.
27. Pan SS, Akman SA, Forrest GL, Hipsher C, Johnson R. The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells. Cancer Chemother Pharmacol 1992;31:23-31.
28. Lee JH, Naito M, Nakajima M, Tsuruo T. Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells. Cancer Chemother Pharmacol 1993;33:215-20.
29. Nishiyama M, Saeki S, Aogi K, Hirabayashi N, Toge T. Relevance of DTdiaphorase activity to mitomycin C (MMC) efficacy on human cancer cells: differences in in vitro and in vivo systems. Int J Cancer 1993;53:1013-6. (Pubitemid 23119553)
30. Begleiter A, Leith MK. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under acidic conditions. Mol Pharmacol 1993;44:210-5. (Pubitemid 23230479)
31. Bando T, Kasahara K, Shibata K, Nakatsumi Y, Fujimura M, Matsuda T. Role of dt-diaphorase as a determinant of sensitivity to mitomycin analogs in non-small cell lung-cancer cell-lines. Int J Oncol 1994;5:819-25. (Pubitemid 24293359)
32. Shibata K, Kasahara K, Bando T, Nakatsumi Y, Fujimura M, Tsuruo T, et al. Establishment and characterization of non-small cell lung cancer cell lines resistant to mitomycin C under aerobic conditions. Jpn J Cancer Res 1995;86:460-9.
33. Yoshida T, Tsuda H. Gene targeting of DT-diaphorase in mouse embryonic stem cells: establishment of null mutant and its mitomycin C-resistance. Biochem Biophys Res Commun 1995;214:701-8.
34. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996;88:259-69.
35. Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T, Tsuruo T. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res 1996;56:2823-6. (Pubitemid 26175742)
36. Begleiter A, Leith MK, Curphey TJ. Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents. Br J Cancer Suppl 1996;27:S9-14.
37. Wang X, Doherty GP, Leith MK, Curphey TJ, Begleiter A. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase. Br J Cancer 1999;80:1223-30. (Pubitemid 29264083)
38. Suzuki K, Yamamoto W, Park JS, Hanaoka H, Okamoto R, Kirihara Y, et al. Regulatory network of mitomycin C action in human colon cancer cells. Jpn J Cancer Res 1999;90:571-7. (Pubitemid 29267712)
39. Seow HA, Penketh PG, Belcourt MF, Tomasz M, Rockwell S, Sartorelli AC. Nuclear overexpression of NAD(P)H:quinone oxidoreductase 1 in Chinese hamster ovary cells increases the cytotoxicity of mitomycin C under aerobic and hypoxic conditions. J Biol Chem 2004;279:31606-12. (Pubitemid 39037830)
40. Nishiyama M, Suzuki K, Kumazaki T, Yamamoto W, Toge T, Okamura T, et al. Molecular targeting of mitomycin C chemotherapy. Int J Cancer 1997;72:649-56. (Pubitemid 27356168)
41. Lin YL, Ho IC, Su PF, Lee TC. Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression. Toxicol Appl Pharmacol 2006;214:309-17.
42. Keyes SR, Heimbrook DC, Fracasso PM, Rockwell S, Sligar SG, Sartorelli AC. Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C. Adv Enzyme Regul 1985;23:291-307.
43. Keyes SR, Rockwell S, Sartorelli AC. Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro. Cancer Res 1985;45:213-6. (Pubitemid 15196957)
44. Dulhanty AM, Whitmore GF. Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase. Cancer Res 1991;51:1860-5.
45. Bizanek R, Chowdary D, Arai H, Kasai M, Hughes CS, Sartorelli AC, et al. Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns. Cancer Res 1993;53:5127-34. (Pubitemid 23333377)
46. Siegel D, Beall H, Senekowitsch C, Kasai M, Arai H, Gibson NW, et al. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry 1992;31:7879-85.
47. Siegel D, Beall H, Kasai M, Arai H, Gibson NW, Ross D. pH-dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin. Mol Pharmacol 1993;44:1128-34. (Pubitemid 24008594)
48. Pan SS, Yu F, Hipsher C. Enzymatic and pH modulation of mitomycin C-induced DNA damage in mitomycin C-resistant HCT 116 human colon cancer cells. Mol Pharmacol 1993;43:870-7. (Pubitemid 23178862)
49. Kennedy KA, McGurl JD, Leondaridis L, Alabaster O. pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells. Cancer Res 1985;45:3541-7. (Pubitemid 15226421)
50. Sharp SY, Kelland LR, Valenti MR, Brunton LA, Hobbs S, Workman P. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol 2000;58:1146-55.
51. Winski SL, Hargreaves RH, Butler J, Ross D. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin Cancer Res 1998;4:3083-8. (Pubitemid 29001485)
52. Cowen RL, Patterson AV, Telfer BA, Airley RE, Hobbs S, Phillips RM, et al. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. Mol Cancer Ther 2003;2:901-9.
53. Begleiter A, Leith MK, Thliveris JA, Digby T. Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo. Br J Cancer 2004;91:1624-31. (Pubitemid 39486372)
54. Eickelmann P, Schulz WA, Rohde D, Schmitz-Drager B, Sies H. Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe Seyler 1994;375:439-45. (Pubitemid 2120331)
55. Perry RR, Kang Y, Greaves B. Biochemical characterization of a mitomycin C resistant colon cancer cell line variant. Biochem Pharmacol 1993;46:1999-2005. (Pubitemid 23361907)
56. Xu BH, Gupta V, Singh SV. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. Int J Cancer 1994;58:686-92. (Pubitemid 24279432)
57. Xu BH, Gupta V, Singh SV. Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue. Br J Cancer 1994;69:242-6. (Pubitemid 24046544)
58. Ward TH, Haran MS, Whittaker D, Watson AJ, Howard TD, Butler J. Cross-resistance studies on two K562 sublines resistant to diaziridinylbenzoquinones. Biochem Pharmacol 1995;50:459-64.
59. Singh SV, Xu BH, Gupta V, Emerson EO, Zaren HA, Jani JP. Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C. Cancer Lett 1995;95:49-56.
60. Lambert PA, Kang Y, Greaves B, Perry RR. The importance of DT-diaphorase in mitomycin C resistance in human colon cancer cell lines. J Surg Res 1998;80:177-81. (Pubitemid 29019666)
61. Baumann RP, Hodnick WF, Seow HA, Belcourt MF, Rockwell S, Sherman DH, et al. Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells. Cancer Res 2001;61:7770-6. (Pubitemid 33049363)
62. Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, et al. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl. Cancer Res 1992;52:4752-7.
63. Phillips RM, Burger AM, Fiebig HH, Double JA. Genotyping of NAD(P)H:quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to mitomycin C chemotherapy in vivo(1). Biochem Pharmacol 2001;62:1371-7. (Pubitemid 33044683)
64. Fleming RA, Drees J, Loggie BW, Russell GB, Geisinger KR, Morris RT, et al. Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C. Pharmacogenetics 2002;12:31-7. (Pubitemid 34112240)
65. Gan Y, Mo Y, Kalns JE, Lu J, Danenberg K, Danenberg P, et al. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. Clin Cancer Res 2001;7:1313-9. (Pubitemid 32708686)
66. Basu S, Brown JE, Flannigan GM, Gill JH, Loadman PM, Martin SW, et al. Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. Int J Cancer 2004;109:703-9. (Pubitemid 38405617)
67. Basu S, Brown JE, Flannigan GM, Gill JH, Loadman PM, Martin SW, et al. NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C. Int J Oncol 2004;25:921-7.
68. Buzdar AU, Tashima CK, Blumenschein GR, Hortobagyi GN, Yap HY, Krutchik AN, et al. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. Cancer 1978;41:392-5. (Pubitemid 8289249)
69. Adikesavan AK, Barrios R, Jaiswal AK. In vivo role of NAD(P)H:quinone oxidoreductase 1 in metabolic activation of mitomycin C and bone marrow cytotoxicity. Cancer Res 2007;67:7966-71. (Pubitemid 47395126)
70. Boveris A, Docampo R, Turrens JF, Stoppani AO. Effect of beta-lapachone on superoxide anion and hydrogen peroxide production in Trypanosoma cruzi. Biochem J 1978;175:431-9. (Pubitemid 9060101)
71. Boorstein RJ, Pardee AB. Coordinate inhibition of DNA synthesis and thymidylate synthase activity following DNA damage and repair. Biochem Biophys Res Commun 1983;117:30-6.
72. Boorstein RJ, Pardee AB. Beta-lapachone greatly enhances MMS lethality to human fibroblasts. Biochem Biophys Res Commun 1984;118:828-34. (Pubitemid 14194795)
73. Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. Cancer Res 1989;49:605-12. (Pubitemid 19050323)
74. Li CJ, Averboukh L, Pardee AB. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem 1993;268:22463-8. (Pubitemid 23318296)
75. Planchon SM, Wuerzberger-Davis SM, Pink JJ, Robertson KA, Bornmann WG, Boothman DA. Bcl-2 protects against beta-lapachone-mediated caspase 3 activation and apoptosis in human myeloid leukemia (HL-60) cells. Oncol Rep 1999;6:485-92.
76. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 2000;275:5416-24. (Pubitemid 30115173)
77. Planchon SM, Pink JJ, Tagliarino C, Bornmann WG, Varnes ME, Boothman DA. Beta-lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Exp Cell Res 2001;267:95-106. (Pubitemid 32579145)
78. Docampo R, Cruz FS, Boveris A, Muniz RP, Esquivel DM. Beta-lapachone enhancement of lipid peroxidation and superoxide anion and hydrogen peroxide formation by sarcoma 180 ascites tumor cells. Biochem Pharmacol 1979;28:723-8. (Pubitemid 9162813)
79. Tagliarino C, Pink JJ, Dubyak GR, Nieminen AL, Boothman DA. Calcium is a key signaling molecule in beta-lapachone-mediated cell death. J Biol Chem 2001;276:19150-9.
80. Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, et al. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy. Clin Cancer Res 2011;17:275-85.
81. Choi EK, Terai K, Ji IM, Kook YH, Park KH, Oh ET, et al. Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia 2007;9:634-42. (Pubitemid 47328082)
82. Suzuki M, Amano M, Choi J, Park HJ, Williams BW, Ono K, et al. Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro. Radiat Res 2006;165:525-31.
83. Boothman DA, Meyers M, Fukunaga N, Lee SW. Isolation of X-ray-inducible transcripts from radioresistant human melanoma cells. Proc Natl Acad Sci USA 1993;90:7200-4. (Pubitemid 23222417)
84. Song CW, Chae JJ, Choi EK, Hwang TS, Kim C, Lim BU, et al. Anti-cancer effect of bio-reductive drug beta-lapachon is enhanced by activating NQO1 with heat shock. Int J Hyperthermia 2008;24:161-9. (Pubitemid 351279956)
85. Dong GZ, Youn H, Park MT, Oh ET, Park KH, Song CW, et al. Heat shock increases expression of NAD(P)H:quinone oxidoreductase (NQO1), mediator of beta-lapachone cytotoxicity, by increasing NQO1 gene activity and via Hsp70-mediated stabilisation of NQO1 protein. Int J Hyperthermia 2009;25:477-87.
86. Park HJ, Choi EK, Choi J, Ahn KJ, Kim EJ, Ji IM, et al. Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of betalapachone. Clin Cancer Res 2005;11:8866-71. (Pubitemid 43005939)
87. Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci USA 2007;104:11832-7. (Pubitemid 47175098)
88. Awadallah NS, Dehn D, Shah RJ, Russell Nash S, Chen YK, Ross D, et al. NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol 2008;16:24-31.
89. Ough M, Lewis A, Bey EA, Gao J, Ritchie JM, Bornmann W, et al. Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. Cancer Biol Ther 2005;4:95-102. (Pubitemid 41350938)
90. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 1970;23:442-7.
91. BeBoer C, Dietz A. The description and antibiotic production of Streptomyces hygroscopicus var. Geldanus. J Antibiot (Tokyo) 1976;29:1182-8.
92. Yamaki H, Iguchi-Ariga SM, Ariga H. Inhibition of c-myc gene expression in murine lymphoblastoma cells by geldanamycin and herbimycin, antibiotics of benzoquinoid ansamycin group. J Antibiot (Tokyo) 1989;42:604-10. (Pubitemid 19119102)
93. Li LH, Clark TD, Cowie CH, Rinehart Jr KL. Effects of geldanamycin and its derivatives on RNA-directed DNA polymerase and infectivity of Rauscher leukemia virus. Cancer Treat Rep 1977;61:815-24. (Pubitemid 8167607)
94. Yamaki H, Suzuki H, Choi EC, Tanaka N. Inhibition of DNA synthesis in murine tumor cells by geldanamycin, an antibiotic of the benzoquinoid ansamycin group. J Antibiot (Tokyo) 1982;35:886-92. (Pubitemid 12023576)
95. Uehara Y, Hori M, Takeuchi T, Umezawa H. Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 1986;6:2198-206. (Pubitemid 17189579)
96. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994;91:8324-8.
97. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17- demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998;42:273-9. (Pubitemid 28393843)
98. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002;21:1159-66. (Pubitemid 34185232)
99. Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 30-kinase-AKT-dependent pathway. Cancer Res 2002;62:3132-7. (Pubitemid 34602405)
100. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001;61:1799-804. (Pubitemid 32691987)
101. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino-17- demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004;103:1078-84. (Pubitemid 38129574)
102. Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, et al. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. Leuk Res 2006;30:575-82. (Pubitemid 43374587)
103. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 2001;7:2076-84. (Pubitemid 32994847)
104. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-15.
105. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
106. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:-quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 2005;65:10006-15. (Pubitemid 41541482)
107. Guo W, Reigan P, Siegel D, Ross D. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action. Drug Metab Dispos 2008;36:2050-7.
108. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol 2006;70:1194-203. (Pubitemid 44435970)
109. Guo W, Siegel D, Ross D. Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation. J Pharm Sci 2008;97:5147-57.
110. Siegel D, Shieh B, Yan C, Kepa JK, Ross D. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells. J Pharmacol Exp Ther 2011;336:874-80.
111. Reigan P, Siegel D, Guo W, Ross D. A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins. Mol Pharmacol 2011;79:823-32.
112. Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 2009;69:1966-75.
113. Douglas M, Lim AR, Porter JR, West K, Pink MM, Ge J, et al. The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo. Mol Cancer Ther 2009;8:3369-78.
114. Zajac M, Gomez G, Benitez J, Martinez-Delgado B. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer. BMC Med Genomics 2010;3:44.
115. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87. (Pubitemid 46202262)
116. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K, et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008;40:844-53. (Pubitemid 351913646)
117. Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, et al. Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenet Genomics 2011;21:808-19.